SCHEMBL4046879

SCHEMBL4046879

CCOC(=O)c1[nH]c2c(Cl)c(Cl)ccc2c1C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
HPGD P15428 4/20 0.48
MAPT P10636 4/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALOX15 P16050 4/20 0.46
GAA P10253 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4042141 0.90 MAPT (0.49) ALDH1A1HPGDMAPTRAB9AKDM4E
SCHEMBL26912249 0.86 CDK1 (0.46) ALDH1A1HPGDMAPTCYP1A2CYP2C9
SCHEMBL24573419 0.86 ALOX15 (0.44) ALDH1A1HPGDCYP1A2CYP2C19ALOX15
SCHEMBL4090248 0.83 CDK1 (0.57) ALDH1A1HPGDMAPTRAB9AKDM4E
SCHEMBL31025925 0.82 MAPT (0.50) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL8321153 0.79 CYP1A2 (0.50) ALDH1A1HPGDMAPTRAB9AKDM4E
SCHEMBL13684773 0.78 ALDH1A1 (0.52) ALDH1A1HPGDMAPTRAB9AKDM4E
SCHEMBL8322185 0.77 MAPT (0.49) ALDH1A1HPGDMAPTRAB9AKDM4E
SCHEMBL1254811 0.77 MCL1 (0.51) ALDH1A1HPGDMAPTRAB9AKDM4E
SCHEMBL1252207 0.75 ALDH1A1 (0.49) ALDH1A1HPGDMAPTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370561-B1 TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS HOFFMANN LA ROCHE (CH) 2009-02-11 EP disclosed
US-6844345-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-01-18 US disclosed
EP-1370561-A2 TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-12-17 EP disclosed
US-20020169163-A1 Piperazine derivatives HOFFMAN-LA ROCHE INC. 2002-11-14 US disclosed
WO-2002072584-A2 TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169163-A1 Piperazine derivatives GPR119, SLC5A2, DPP4 ALDH1A1 1203/4885HPGD 1383/4885MAPT 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.